DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Moxifloxacin (Avelox, BAY12-8039) (Drug); Moxifloxacin (BAY12-8039) (Drug); Moxifloxacin (BAY12-8039) (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Summary

The purpose of this study is to describe the pharmacokinetics of a new oral liquid moxifloxacin formulation and the influence of concommitant food intake on the pharmacokinetics in healthy adults compared to the marketed oral tablet. Pharmacokinetics is to see how the body absorbs, distributes and gets rid of the study drug. The absorption of the drug administered in a different dosage form may be altered due to the influence of different excipients used. The safety of moxifloxacin when administered as an oral liquid formulation will also be looked at. Results from this study will be used to guide dosing strategies of the larger clinical trial planned for children.

Clinical Details

Official title: Single-dose, Open-label, Randomized, Non-blinded, Three-fold Crossover Study in Healthy Subjects to Compare the Bioavailability of Moxifloxacin (BAY12-8039) 400 mg Tablet and 400 mg Oral Suspension Under Fasting Conditions, and to Investigate the Effect of Food on the Bioavailability of 400 mg Suspension.

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Moxifloxacin after a Single Dose

Maximum Observed Drug Concentration (Cmax) of Moxifloxacin after a Single Dose

Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose(AUC/D) of Moxifloxacin after a Single Dose

Maximum Observed Drug Concentration Adjusted by Dose (Cmax/D) of Moxifloxacin after a Single Dose

Secondary outcome:

Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm) of Moxifloxacin after a Single Dose

Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration [AUC(0-tlast)] of Moxifloxacin after a Single Dose

Maximum Observed Plasma Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm) of Moxifloxacin after a Single Dose

Mean Residence Time (MRT) of Moxifloxacin after a Single Dose

Time to Reach Maximum Drug Concentration in Plasma (tmax) of Moxifloxacin after a Single Dose

Terminal Half Life Associated With the Terminal Slope (t1/2) of Moxifloxacin after a Single Dose

Apparent Oral Clearance (CL/F) of Moxifloxacin after a Single Dose

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy male and female subjects;

- Age: 18 to 55 years (inclusive)

- Body mass index (BMI): above/equal 18 and below/equal 30 kg/m²;

- Women of childbearing age must have a negative pregnancy test and must use adequate

contraception throughout the study and for 4 weeks afterwards Exclusion Criteria:

- Clinically relevant findings in the ECG

- Incompletely cured pre-existing diseases for which it can be assumed that the

absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal

- Known hypersensitivity to moxifloxacin, other quinolones or to any of the excipients

- Known severe allergies, non-allergic drug reactions, or multiple drug allergies

- Relevant diseases within the last 4 weeks prior to the first study drug

administration

- Febrile illness within 1 week before the first study drug administration

- Patients with a history of tendon disease/disorder related to quinolone treatment.

- Congenital or documented acquired QT prolongation

- Regular use of medicines (with the exception of contraceptives)

- Pregnancy or lactation

- Regular use of therapeutic or recreational drugs

- Smoking more than 25 cigarettes daily

- Regular daily consumption of more than 500 mL of usual beer or the equivalent

quantity of approximately 20 g of alcohol in another form

- Suspicion of drug or alcohol abuse

- Special diets preventing the subjects from eating the standard meals during the study

- Regular daily consumption of more than 1 L of xanthin-containing beverages

- Donation of more than 100 mL of blood within 4 weeks before the first study drug

administration or of approximately 500 mL in the preceding 3 months

Locations and Contacts

Wuppertal, Nordrhein-Westfalen 42096, Germany
Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Click here to find information about studies related to Bayer Healthcare products conducted in Europe

Starting date: May 2010
Last updated: June 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017